Timothy A. Springer, Director, 10% Owner at Cartesian Therapeutics, Inc. (RNAC), bought 863,880 shares at $17.09 ($14.7M) on 2024-11-15, disclosed to the SEC on 2024-11-18.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $16.19 | 74,157 | $1.2M | 8.1% |
| 2 | $16.19 | 74,157 | $1.2M | 8.1% |
| 3 | $16.97 | 22,242 | $377K | 2.6% |
| 4 | $16.97 | 22,242 | $377K | 2.6% |
| 5 | $17.09 | 277,246 | $4.7M | 32.1% |
| 6 | $17.09 | 277,246 |
| $4.7M |
| 32.1% |
| 7 | $17.96 | 38,114 | $685K | 4.6% |
| 8 | $17.96 | 38,114 | $685K | 4.6% |
| 9 | $18.42 | 20,181 | $372K | 2.5% |
| 10 | $18.42 | 20,181 | $372K | 2.5% |
| Total | $17.07 avg | 863,880 | $14.7M | 100% |
| Filing → |
| TECX | BUY | 2025-04-09 | $17.1M | — | Filing → |
| RNAC | BUY | 2025-03-20 | $2.7M | — | Filing → |
| TECX | BUY | 2025-02-07 | $47.0M | — | Filing → |